Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Recombinant human erythropoietin (r-HuEpo) has been used to treat renal anemia and improve
morbidity and mortality in chronic kidney disease. Subcutaneous use of r-HuEpo causes
immunogenicity and develops anti-r-HuEpo associated pure red cell aplasia (PRCA). The
treatment of anti-r-HuEpo associated pure red cell aplasia is controversial. The
investigators aim to evaluate the treatment for anti-r-HuEpo associated pure red cell aplasia
in this study.